sarcoglycanopathy
Showing 1 - 5 of 5
LGMD2C Trial (ATA-200)
Not yet recruiting
- LGMD2C
- ATA-200
- (no location specified)
Aug 1, 2023
LGMD2E/R4, LGMD2D/R3, and LGMD2C/R5, = 4 Years of Age, Who Are
Recruiting
- Limb-girdle Muscular Dystrophy
-
Phoenix, Arizona
- +14 more
Aug 23, 2022
Genetics of Cardiovascular and Neuromuscular Disease
Recruiting
- Cardiomyopathy
- +2 more
- Blood draw (genetic testing)
-
Chicago, IllinoisUniversity of Chicago
Aug 23, 2016
Muscular Dystrophies Trial in Columbus (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort, Genetic:
Completed
- Muscular Dystrophies
- rAAV1.tMCK.human-alpha-sarcoglycan- First cohort
- Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
-
Columbus, OhioThe Research Institute at Nationwide Children's Hospital
Feb 4, 2013
Limb Girdle Muscular Dystrophy Type 2C, Gamma-sarcoglycanopathy Trial in Paris (AAV1-gamma-sarcoglycan vector injection)
Completed
- Limb Girdle Muscular Dystrophy Type 2C
- Gamma-sarcoglycanopathy
- AAV1-gamma-sarcoglycan vector injection
-
Paris, FranceHôpital Pitié-Salpêtrière
Apr 28, 2011